Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Oculis S.A.

Finance Watch: Dyno Therapeutics Raises $100m For Novel AAV Vectors

Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round. 

Finance Watch Financing

Eye Specialist Oculis Launching Four Key Clinical Studies

The CEO of Oculis tells Scrip the Swiss biotech can become a major ophthalmic player and that its lead asset could become the first topical drug treatment for retinal edema.

Clinical Trials Ophthalmic

Oculis’s OCS-01 Sparkles Treating Front-Of-Eye Inflammation

Oculis’s eyedrop OCS-01 showed high efficacy treating post-cataract inflammation in front of the eye, adding to its effective use in back-of-the-eye conditions.

Clinical Trials Companies

Interview: Oculis Closes In On The Dream of DME Eyedrops

The Swiss biotech believes the clinical success of OCS-01, a novel eye drop formulation of dexamethasone for diabetic macular edema, validates not only the drug but also Oculis's proprietary technology, allowing it to build up a pipeline of products for both retinal and front of the eye diseases.

Ophthalmic Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register